Stockscreener 앱 받기
1.08
3.57%
-0.04
Lexicon Pharmaceuticals Inc 주식(LXRX)의 최신 뉴스
Trendline Breach Raises Concern for Lexicon Pharmaceuticals Inc. InvestorsWeekly Return Pick Forecast Reports Show Trend - metal.it
Citigroup Boosts Lexicon Pharmaceuticals Price Target, Maintains 'Buy' Rating. - AInvest
Lexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy - TipRanks
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges - TipRanks
Citigroup Raises Lexicon Pharmaceuticals PT to $1.9, Maintains Buy Rating - AInvest
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals 2025 Q2 Earnings Remarkable Turnaround with 106.1% Net Income Increase - AInvest
Lexicon: Q2 Earnings Snapshot - Greenwich Time
Lexicon Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 By Investing.com - Investing.com Australia
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 - Investing.com
Lexicon Pharmaceuticals’ Q2 2025: Navigating Contradictions in Trial Designs, Partnering Strategies, and Financial Guidance - AInvest
Lexicon Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals Reports Surprising Q2 Earnings and RevenueNews and Statistics - IndexBox
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates - sharewise.com
LEXICON PHARMACEUTICALS Earnings Results: $LXRX Reports Quarterly Earnings - Quiver Quantitative
Lexicon Pharmaceuticals Inc (LXRX) Reports Q2 2025 Earnings: EPS - GuruFocus
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharmaceuticals reports Q2 results, Phase 2b PROGRESS study results, and Q3 enrollment target. - AInvest
Evaluating Lexicon Pharmaceuticals' Q2 2025 Earnings and Institutional Investor Sentiment: A Path to Value Creation Amid Mixed Analyst Ratings - AInvest
Published on: 2025-08-04 19:08:28 - metal.it
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
Is Lexicon Pharmaceuticals Inc. stock overvalued or undervaluedBuild a winning investment strategy - Jammu Links News
Published on: 2025-08-04 02:57:12 - Jammu Links News
What is the risk reward ratio of investing in Lexicon Pharmaceuticals Inc. stockMarket-beating performance - Jammu Links News
What are Lexicon Pharmaceuticals Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyBuild a diversified portfolio for risk management - Jammu Links News
What are analysts’ price targets for Lexicon Pharmaceuticals Inc. in the next 12 monthsInvest smarter with real-time trading signals - Jammu Links News
What is the dividend policy of Lexicon Pharmaceuticals Inc. stockConsistent triple returns - Jammu Links News
Does Lexicon Pharmaceuticals Inc. stock perform well during market downturnsGet timely alerts on market movers - Jammu Links News
Should I hold or sell Lexicon Pharmaceuticals Inc. stock in 2025Tap into rapid wealth building techniques - Jammu Links News
Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable trading performance - Jammu Links News
How does Lexicon Pharmaceuticals Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
What drives Lexicon Pharmaceuticals Inc. stock priceSky-high profits - Jammu Links News
How volatile is Lexicon Pharmaceuticals Inc. stock compared to the marketCapitalize on momentum-driven stocks - Jammu Links News
Is Lexicon Pharmaceuticals Inc. a growth stock or a value stockBuild a portfolio with strong long-term growth - Jammu Links News
How does Lexicon Pharmaceuticals Inc. compare to its industry peersPre Market Forecasts For Smart Trading - Jammu Links News
Why Lexicon Pharmaceuticals Inc. stock attracts strong analyst attentionLow Risk Swing Trade Opportunities Identified - metal.it
Will Lexicon Pharmaceuticals Inc. continue its uptrendRisk Controlled Picks With Real Returns Outlined - metal.it
Lexicon Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Lexicon Pharmaceuticals Regains Nasdaq Compliance with Bid Price Requirement - AInvest
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Lexicon Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com UK
How sentiment analysis helps forecast Lexicon Pharmaceuticals Inc.Capital Protection Trading Strategies Gain Interest - metal.it
Technical Charts Suggest Momentum Shift in Lexicon Pharmaceuticals Inc.High Return Stock Focus With Safety Emphasized - metal.it
Lexicon Pharmaceuticals Meets Nasdaq Bid Price Requirement, Boosting Market Position - AInvest
Why is Lexicon Pharmaceuticals Inc. stock attracting strong analyst attentionExpert Picks Guidance For 2025 - jammulinksnews.com
How strong is Lexicon Pharmaceuticals Inc. company’s balance sheetDynamic investment growth - jammulinksnews.com
0.24%
3.39%
자본화:
|
볼륨(24시간):